NeuroNOS BA-101 Granted FDA Orphan Drug Designation for Glioblastoma Treatment.

NeuroNOS, a biopharmaceutical company, has been granted Orphan Drug Designation by the FDA for its investigational therapy, BA-101, to treat Glioblastoma, the most common and deadliest primary malignant brain cancer in adults. The designation allows for market exclusivity and other incentives for the development and commercialization of BA-101.

NeuroNOS, a biopharmaceutical company, has been granted Orphan Drug Designation (ODD) by the FDA for its investigational therapy, BA-101, to treat Glioblastoma (GBM), the most common and deadliest primary malignant brain cancer in adults. The designation, announced on September 8, 2025, provides regulatory advantages that include market exclusivity and other incentives for the development and commercialization of BA-101 [1].

Glioblastoma, an aggressive primary brain tumor, has limited treatment options with a median survival of less than 12 months, and survival rates of less than 20% at two years and less than 10% at five years [1]. The FDA's ODD for NeuroNOS's glioblastoma therapy marks the company's second designation and its entry into the oncology field. The designation provides several benefits, including seven years of market exclusivity, tax credits for clinical trials, and prescription drug user fee waivers [1].

NeuroNOS's approach to treating glioblastoma focuses on an NO inhibition strategy, supported by research showing nitric oxide as an important modulator in GBM treatment response [1]. The company's CEO, Amir Avniel, stated that the ODD highlights the company's mission to bring targeted therapies to individuals and families affected by rare neurological conditions, while also marking their entrance into oncology [1].

The FDA grants ODD to drugs and biologics intended for safe and effective treatment, diagnosis, or prevention of rare diseases or disorders affecting fewer than 200,000 people in the U.S. [1]. NeuroNOS's lead CSO, Prof. Haitham Amal, expressed commitment to working closely with regulators, investigators, patient groups, and foundations to accelerate the development of BA-101 toward first-in-human studies [1].

NeuroNOS is at the forefront of developing innovative treatments for neurodevelopmental and neurodegenerative disorders. The company specializes in creating therapies based on small molecules that cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain [1]. NeuroNOS's research has shown that managing NO levels in the brain is crucial for maintaining normal brain function.

Beyond Air, Inc., the parent company of NeuroNOS, is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous Nitric Oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors [1]. The company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.

The FDA's Orphan Drug Designation for NeuroNOS's glioblastoma therapy provides regulatory advantages but also presents challenges related to the completion of the offering, risks related to the ability to raise additional capital, the timing and results of future pre-clinical studies and clinical trials, and the potential that regulatory authorities may not grant or may delay approval for the product candidates [1].

References:

[1] https://finance.yahoo.com/news/neuronos-granted-fda-orphan-drug-120000765.html
[2] https://www.stocktitan.net/news/XAIR/neuro-nos-granted-fda-orphan-drug-designation-for-glioblastoma-the-56vtkdrvf7l5.html